What Does the Published Research Say About NA Semax Amidate?

What This Article Covers

This article summarizes the published-research position for NA Semax Amidate as a distinct Semax-family product. It separates exact-compound evidence from adjacent Semax literature so the reader can see where the evidence starts and stops.

Bottom Line

No direct PubMed-indexed human intervention studies were identified for the exact phrase NA Semax Amidate or N-acetyl Semax Amidate in the source check used for this article. Parent-compound Semax literature is useful context, but it should not be treated as direct evidence for the N-acetyl amidated variant.

What Was Tested in Humans?

No controlled human intervention data for NA Semax Amidate were identified in the selected source set. The parent Semax literature includes a human study in patients with motor neuron disease, but that study should not be transferred to an amidated variant without direct evidence for the variant [pubmed:18379501].

What Do Reviews and Evidence Syntheses Add?

Review literature places Semax and related neuroactive peptides in neuroimmune and therapeutic-peptide discussions [pubmed:28875850][pubmed:41490200]. These reviews provide background on the field but do not establish outcomes for NA Semax Amidate.

What Did Animal and Mechanistic Studies Show?

Parent Semax studies include rat basal-forebrain BDNF work [pubmed:16635254], rat ischemia-model work [pubmed:20617398], mouse spinal-cord-injury work [pubmed:40692165], experimental hemostasis studies [pubmed:11687836], rat serum enzyme-degradation work [pubmed:8392718], and systems-level Selank/Semax functional-connectomic research [pubmed:32342318]. Arachidonoyl derivatives of amino acids and peptides including Semax have also been synthesized and characterized in biochemical assays [pubmed:16808168].

These studies are context for Semax-family research. They do not establish direct findings for the NA Semax Amidate variant.

How the Evidence Fits Together

The practical reading for NA Semax Amidate is variant specificity. Parent Semax evidence may explain why researchers study this family, but chemical or terminal modifications can affect stability, assay behavior, distribution, and interpretation. Variant evidence should control variant claims.

What Is Not Established

• Direct human efficacy or safety for NA Semax Amidate is not established in the selected source set.
• Parent Semax findings should not be transferred automatically to NA Semax Amidate.
• Animal, cellular, or review-level findings should not be converted into human-use claims.
• Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.

Research-Use Boundary

This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.

Selected Sources

• PubMed exact-query context for N-acetyl Semax Amidate: https://pubmed.ncbi.nlm.nih.gov/?term=%22N-acetyl+Semax+amidate%22
• [pubmed:18379501] The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with Semax. https://pubmed.ncbi.nlm.nih.gov/18379501/
• [pubmed:16635254] Semax binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. https://pubmed.ncbi.nlm.nih.gov/16635254/
• [pubmed:20617398] The effect of Semax and its C-end peptide PGP on rat brain cells during experimental ischemia. https://pubmed.ncbi.nlm.nih.gov/20617398/
• [pubmed:40692165] Semax peptide targets Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. https://pubmed.ncbi.nlm.nih.gov/40692165/
• [pubmed:11687836] Comparative study of modulatory effects of Semax and primary proline-containing peptides on hemostatic reactions. https://pubmed.ncbi.nlm.nih.gov/11687836/
• [pubmed:8392718] Degradation of ACTH/MSH(4-10) and Semax by rat serum enzymes. https://pubmed.ncbi.nlm.nih.gov/8392718/
• [pubmed:16808168] Arachidonoyl amino acids and arachidonoyl peptides: synthesis and properties. https://pubmed.ncbi.nlm.nih.gov/16808168/
• [pubmed:32342318] Functional Connectomic Approach to Studying Selank and Semax Effects. https://pubmed.ncbi.nlm.nih.gov/32342318/
• [pubmed:28875850] Pharmacological Aspects of Neuro-Immune Interactions. https://pubmed.ncbi.nlm.nih.gov/28875850/

Related KRL Resources

• Research Compound Catalog
• Technical Products
• FAQ